BlessUp Peptide Library · Brain & Cognition
Semax, Selank, Cerebrolysin, and Dihexa all promise a better brain, through four different mechanisms and four very different levels of proof.
The mechanisms are intriguing. The evidence is uneven, and one of them just lost its foundation.
Dihexa's key 2014 mechanism paper was retracted in 2025 for fabricated data. Cerebrolysin has the most human trials, with mixed results. Full citations at the end.
You have seen them grouped as "nootropic peptides," as if they were interchangeable brain-boosters: Semax for focus, Selank for calm, Cerebrolysin for recovery, Dihexa for raw synapse-building. They are not interchangeable, and they are not equally proven.
Here is the honest version. Each of these works through a genuinely different mechanism, and each sits on a different rung of the evidence ladder. The mechanisms are interesting, sometimes elegant. But the human proof is thin and uneven: strongest (though still only modest) for one of them, mostly from Russian-language studies for two, and essentially absent for the trendiest one, whose headline research paper was retracted for fabricated data in 2025. This is a class where the marketing and the mechanism have run well ahead of the evidence, so the useful thing we can do is line up the mechanism against the proof, honestly, one compound at a time. We do honest, not hype.
Read this first
This is education, not medical advice, and it does not replace your own clinician. None of these is FDA-approved. Cerebrolysin is an injectable, animal-derived medicine approved in some countries; Semax and Selank are prescription drugs in Russia; Dihexa is a research compound with no human trials. Anything named here is an example for discussion, never a prescription. For anything clinical, especially Cerebrolysin, a provider belongs in the loop.
90-second self-check
This flags the safety stops, and if you are clear, points toward the compound that matches your goal, and away from the one that is not ready. It is education, not a diagnosis or a recommendation to use anything.
Answer honestly. Nothing is stored, and no one sees it but you.
First, the hard stops. Do any of these apply to you? (tap all that are true)
What are you actually weighing this class for?
Any of these in your picture? (tap all that apply)
Is the foundation actually in place? (tap all that apply)
This reflection is education only, not a diagnosis or a recommendation to use any compound. Talk to a licensed provider about your own history and goals.
The basics
The thing that groups these together is loose: they are all peptides studied for the brain. But they work through genuinely different mechanisms, and the honest way to hold them apart is by mechanism and by evidence at the same time.
| Compound | Mechanism | Studied for | Evidence level | Route |
|---|---|---|---|---|
| Semax | ACTH fragment → BDNF | Focus, neuroprotection, stroke | Approved in Russia; mostly Russian studies | Intranasal / SubQ |
| Selank | Tuftsin → GABA calm | Anxiety without sedation | Approved in Russia; mostly Russian studies | Intranasal / SubQ |
| Cerebrolysin | Multi-peptide neurotrophic mix | Stroke, dementia, brain injury | Most human trials; results mixed | IM / IV (clinical) |
| Dihexa | HGF / c-Met synaptogenesis | Synapses, memory (animal models) | Preclinical only; key paper retracted | Oral / SubQ (experimental) |
A fifth, P-21, sits with Dihexa on the preclinical-only tier (animal data, no human trials), with a cleaner record. It is worth knowing exists, not worth treating as proven.
The honest half-truth you will hear
"These are proven brain-boosters." Half true, and the halves matter. Cerebrolysin has real trials, but the results are modest and mixed. Semax and Selank have genuine human data, but it is largely Russian-language and does not meet Western trial standards. And Dihexa, the one with the most exciting story, has no human trials at all, and the paper that established its mechanism was retracted for fabricated data. Interesting mechanism is not the same as proven benefit.
The part the marketing flips
These get sold as if they are equally legitimate cognitive tools. They are not, and the differences are large. Here is an honest read of how much real human evidence sits behind each. Longer bars mean deeper, more rigorous human data, not "feels stronger."
Depth of human evidence, by compound
A judgment read of the literature. Even the leader is only modest; the trendiest one is preclinical, and its foundation was retracted.
Cerebrolysin: Gauthier 2015 (positive AD meta) alongside the 2023 Cochrane review (no stroke benefit). Selank: Zozulia 2008 (Russian RCT vs a benzodiazepine). Dihexa: foundational 2014 mechanism paper retracted 2025. Full citations below.
Read the shape honestly. Cerebrolysin leads, but "leads" here means real trials with modest and inconsistent results, not a settled win. Semax and Selank are real but under-vetted in the West. And Dihexa sits at the bottom not because the idea is bad, but because there is no human evidence and its clearest mechanistic paper no longer stands.
Under the hood
Activates brain melanocortin receptors to push up BDNF and related growth factors and blood flow, sharpening focus, without raising cortisol the way its parent hormone would.
Nudges the GABA calming system (without binding the sedative benzodiazepine site) and touches serotonin, easing anxiety without drowsiness, tolerance, or dependence.
A mixture of small peptides that both mimics the brain's growth factors and prompts the brain to make more of its own, while damping inflammation. Not one lever, a cocktail.
Designed to prolong a growth-factor pathway (HGF and its c-Met receptor) that drives new synapse formation. Extremely potent in cell and animal work; the human chain is unproven, and its key paper was retracted.
The four, with honest pros and cons
Different mechanisms, different rungs of proof. Tags show the lean: focus, calm, clinical, or experimental.
A stress-hormone fragment re-tuned to raise the brain's growth signal without the cortisol. The focus and neuroprotection one.
Honest read: the morning focus peptide, real but under-vetted in the West. Intranasal or SubQ, morning only. Classically paired with Selank at night.
A tuftsin-derived peptide that calms without sedating. The anxiety one, and the best-tolerated of the class.
Honest read: the evening calm peptide, genuinely gentle. Intranasal or SubQ. Talk to a provider first if you take psychiatric medication.
Not one molecule but a peptide mixture from pig brain, run as a course of injections. The one with real, if mixed, human trials.
Honest read: promising, not proven, and a clinician's tool. Given by IM or IV in courses, for a specific neurorecovery goal, with a provider. Not a feel-it-today nootropic.
An angiotensin-derived peptide reported to be extraordinarily potent at building synapses in animals. The trendiest, and the least proven.
Honest read: a research story, not a run-it-well compound. The sensible move is to follow the science and wait for human data, not to be the experiment.
Why the honesty matters here
Dihexa is famous online for a stunning number: reportedly far more potent than BDNF at building synapses. That claim traces back to a specific 2014 research paper. According to PubMed, that paper was retracted in 2025 for falsified and fabricated figures (retraction notice doi:10.1016/j.jpet.2025.103567). The remaining studies make the mechanism a reasonable hypothesis to investigate, not a settled fact to market. Add a 2024 animal study that found no benefit, and no human trials at all, and the honest verdict is simple.
The Dihexa verdict
There is no established safety profile, no validated dose, and no human exposure data, and the clearest mechanistic paper no longer stands. This is a compound where the enthusiasm has run far ahead of the evidence. The sensible action is to watch replication and trials from the sidelines, and build the proven neuroplasticity foundation (below) now.
The cautions that matter
These are generally milder than the injectable hormones elsewhere in the library, but "research chemical with limited oversight" is the honest frame for most of them, and a few lines are firm.
These are neuro-active agents, and a seizure signal has been reported with Cerebrolysin at high doses. Any personal or family history of seizures is a reason to stop and talk to a neurologist before considering any of them.
None of these has the safety data to be used in pregnancy or breastfeeding. Clear that first.
No human data means no known safety window. And its growth-factor pathway (c-Met) is involved in cancer biology, so anyone with an active or recent cancer, or a hereditary cancer risk, has especially little basis for accepting that uncertainty.
Cerebrolysin is derived from pig brain, so a known allergy to porcine or biological protein products is a firm contraindication, and a supervised test dose is prudent for the first course regardless.
Selank modulates serotonin, so if you take an SSRI or other serotonergic or psychiatric medication, that is a provider conversation before you add anything here.
The one rule under all of it
Match the compound to a real goal, keep anything clinical (Cerebrolysin above all) with a provider, be honest that Semax and Selank are under-vetted in the West, and leave Dihexa on the shelf until there is human data. And build the foundation below first, because it does more than any of these.
Put it together
First question
Second question
The move most people skip
The biggest cognitive gains in your near future come from sleep, exercise, and learning, not from a vial. Fix those first, then, if you still want to, match the mildest compound to a real goal with honest eyes on the evidence. Matching beats maxing.
The foundation under everything
Memory is consolidated and the brain is cleared and repaired during sleep. No peptide compensates for short or broken sleep, and several of these disrupt it if dosed late. Fix sleep before you spend a dollar on a vial.
Aerobic exercise reliably raises BDNF, the exact growth signal Semax nudges pharmacologically. It is the most evidence-backed cognitive intervention there is, and it is free.
The brain builds connections through use: learning new skills, real cognitive challenge, and social engagement. That is genuine synaptogenesis, with far better evidence than any synapse-building peptide.
Blood-pressure and glucose control, hearing and vision correction, adequate protein and B-vitamins, and treating documented deficiencies do more for long-term cognition than any compound on this page.
Cutting through the noise
The genuinely evidence-backed way to build a better brain. This is what the peptides only nudge on top of. Boring, and it works.
Sensible support with reasonable evidence, especially B12, folate, iron, vitamin D, and thyroid if a lab says you are low. Follow the labs, not the hype.
Each added compound is another layer of unknown interaction on top of already-thin data. More is not more here; it is just more uncertainty.
No human data, a retracted foundational paper, and a cancer-pathway flag. This is the one to leave on the shelf until real human evidence exists.
Turn this into action
Have I ruled out the hard stops: any seizure history, pregnancy, and active or recent cancer?
Is my sleep and exercise actually handled, since those do more than any of these?
Am I honest that Semax and Selank rest on mostly-Russian evidence, and that Dihexa has none?
If I take an antidepressant, have I checked the serotonin interaction with a provider?
For anything clinical like Cerebrolysin, is a provider genuinely involved?
Bring these to your visit
Given my history and medications, is any of this reasonable, and which one?
Does anything I take (especially antidepressants) interact with these?
If Cerebrolysin, is it appropriate for my goal, and how would we monitor it?
What symptoms should make me stop and call you?
A few situations are not "go slower," they are "stop and be seen."
Mild nasal irritation or a short headache settles. A seizure, a breathing reaction, or a sudden mental-state change do not wait. When in doubt, be seen.
The BlessUp take
This is a class where the ideas are genuinely interesting and the evidence is genuinely uneven, and the honest move is to hold both at once. Semax raises the brain's growth signal and Selank calms it, both real medicines in Russia, both under-vetted in the West. Cerebrolysin is the one with real trials, and even it is only modest and mixed, promising in dementia, no survival benefit in stroke. And Dihexa is the cautionary tale of the whole space: a thrilling story, no human data, and a foundational paper retracted for fabrication. So do not buy the mechanism as if it were the outcome. Fix your sleep, your exercise, and your learning first, because those out-perform everything on this page. Then, if you still want to, match the mildest compound to a real goal, keep anything clinical with a provider, and leave the unproven one on the shelf until the science catches up. That is not the timid move. It is the one that respects your brain.
The evidence
Retrieved from PubMed. Cerebrolysin is shown from both sides (a positive dementia meta-analysis and a negative stroke review); the Selank trial is Russian-language; the Dihexa entry is the retraction notice for its foundational mechanism paper. Semax's human evidence is largely Russian-language clinical literature.
Citations retrieved from PubMed. None of these compounds is FDA-approved. Semax and Selank rest largely on Russian-language studies; Dihexa has no human trials and its clearest mechanistic paper has been retracted. This report is an honest educational map of the class, not a dosing sheet or a recommendation to use any compound.